Galapagos Nv

Abbvie S.a.r.l.

Abbvie Overseas Sarl

Elsa De Lemos

Philip R Kym

Xueqing Wang

Gregory A Gfesser

Nicolas Desroy

Christopher Gaëtan Housseman

Béranger Duthion

Marlon D Cowart

Jianguo Ji

Christel Jeanne Marie Menet

Steven Emiel Van Der Plas

Sachin V Patel

Jean-Michel Lefrancois

Luke Jonathan Alvey

Xavier Marie Bock

Oscar Mammoliti

Romain Luc Marie Gosmini

Gregory John Robert Newsome

Pieter Isabelle Roger Claes

Anurupa Shrestha

Rhalid Akkari

Koen Karel Jansen

Adeline Marie Elise Palisse

Elizabeth C Swift

Brian S Brown

Nuria Merayo Merayo

Ann De Blieck

Matthieu Rafaël Pizzonero

Mathieu Rafaël Pizzonero

Robert J Altenbach

John R Koenig

Ming Clinton Yeung

Bo Liu

Marc J Scanio

Xenia Beebe Searle

Andrew Bogdan

Gang Zhao

Stephen N Greszler

Sylvain Couty

Katja Conrath

Chris Tse

Douglas Cyr

Gert Jules Hector De Wilde

The present invention provides for compounds of formula (I) wherein R, R, R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

N-sulfonylated-pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use

A corrector agent capable of stabilizing a newly synthesized cystic fibrosis transmembrane conductance regulator (CFTR) protein, useful in the treatment of cystic fibrosis.

Compounds for treatment of cystic fibrosis

The invention discloses compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

Substituted pyrrolidines and methods of use

The present invention provides for compounds of formula (I) wherein R, R, R, and Rhave any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sj&#xf6;gren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

[object Object]

Growing community of inventors

Paris, France

Elsa De Lemos